| Schedule of Reportable Segment Net Revenues and Loss |
The Company's reportable segment net revenues, significant segment expenses and consolidated loss for the three and six months ended June 30, 2026 and 2025, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
Grant revenue |
$ |
— |
|
|
$ |
2,387 |
|
|
$ |
— |
|
|
$ |
3,150 |
|
Collaboration revenue - related party |
|
— |
|
|
|
11,802 |
|
|
|
258 |
|
|
|
16,901 |
|
Collaboration revenue |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
12 |
|
Total revenues |
|
— |
|
|
|
14,189 |
|
|
|
258 |
|
|
|
20,063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
Tebipenem pivoxil |
|
1,298 |
|
|
|
6,694 |
|
|
|
1,710 |
|
|
|
15,363 |
|
SPR720 |
|
— |
|
|
|
349 |
|
|
|
— |
|
|
|
797 |
|
SPR206 |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
49 |
|
Research and development personnel related (including
share-based compensation) |
|
1,349 |
|
|
|
2,611 |
|
|
|
3,018 |
|
|
|
5,948 |
|
Facility related and other, research and development |
|
787 |
|
|
|
1,018 |
|
|
|
1,615 |
|
|
|
2,121 |
|
General and administrative personnel related (including
share-based compensation) |
|
1,793 |
|
|
|
3,368 |
|
|
|
4,082 |
|
|
|
7,486 |
|
Professional and consultant fees |
|
4,160 |
|
|
|
1,986 |
|
|
|
5,841 |
|
|
|
4,249 |
|
Facility related and other, general and administrative |
|
539 |
|
|
|
524 |
|
|
|
1,456 |
|
|
|
967 |
|
Other segment items* |
|
3 |
|
|
|
79 |
|
|
|
4 |
|
|
|
253 |
|
Interest income |
|
(377 |
) |
|
|
(740 |
) |
|
|
(713 |
) |
|
|
(1,604 |
) |
Consolidated loss |
$ |
(9,552 |
) |
|
$ |
(1,700 |
) |
|
$ |
(16,755 |
) |
|
$ |
(15,566 |
) |
*Other segment items include restructuring charges and other income, net.
|